Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

French obstacles to implantables being lifted:

This article was originally published in Clinica

Executive Summary

After years of delays and obstacles, manufacturers of defibrillators are looking forward to being able to sell their products in the French private healthcare sector for the first time. All that is now left for this to become a reality is for the regional hospital agencies to nominate the hospitals that they have approved to implant these products. Nominations will also be made of clinics allowed to implant DDD:R pacemakers for the first time. This summer has seen the approval by the commission for the evaluation of products and procedures within the healthcare products safety agency of a total of some 23 defibrillators manufactured by St Jude, Ela Medical, Guidant, Medtronic and Biotronik as well as the DDD:R pacemakers. Also achieved has been a pricing agreement between the industry and government intended to limit expenditure on these products.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel